YODA Trademark

Trademark Overview


On Tuesday, August 11, 2020, a trademark application was filed for YODA with the United States Patent and Trademark Office. The USPTO has given the YODA trademark a serial number of 90106080. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Monday, August 23, 2021. This trademark is owned by YODA PHARMACEUTICALS INC.. The YODA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of central nervous system disorders or diseases, namely, neurological illnesses, psychiatric illnesses, and neurodegenerative diseases; pharmaceutical preparations for the treatment of psychiatric, emotional and behavioral disorders, namely, depression, bi-polar disorder, anxiety, panic disorder, schizophrenia, schizoaffective disorder, positive syndrome, negative syndrome, mood and cognitive related symptoms of psychiatric illnesses, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD); pharmaceutical preparations for the treatment of brain injuries, namely, traumatic brain injury (TBI), brain ischemia, post-stroke recovery, post-hemorrhage recovery, reversible cerebral vasoconstriction syndrome, spinal cord injury, convulsion, epileptic seizures; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Parkinson's disease (PD), Alzheimer's disease (AD), dementia, mild cognitive impairment ...
yoda

General Information


Serial Number90106080
Word MarkYODA
Filing DateTuesday, August 11, 2020
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateMonday, August 23, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, July 20, 2021

Trademark Statements


Indication of Colors claimedThe color(s) blue, red, white and green is/are claimed as a feature of the mark.
Description of MarkThe mark consists of the stylized wording "YODA" in blue and the design of a side profile of a human head, with the head and neck thereof in white, brain thereof in green and blue, and white cerebral sulcus thereof in white, overlapping the letter "O". An incomplete oval in red is interwoven with the letters "YOD".
Goods and ServicesPharmaceutical preparations for the treatment of central nervous system disorders or diseases, namely, neurological illnesses, psychiatric illnesses, and neurodegenerative diseases; pharmaceutical preparations for the treatment of psychiatric, emotional and behavioral disorders, namely, depression, bi-polar disorder, anxiety, panic disorder, schizophrenia, schizoaffective disorder, positive syndrome, negative syndrome, mood and cognitive related symptoms of psychiatric illnesses, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD); pharmaceutical preparations for the treatment of brain injuries, namely, traumatic brain injury (TBI), brain ischemia, post-stroke recovery, post-hemorrhage recovery, reversible cerebral vasoconstriction syndrome, spinal cord injury, convulsion, epileptic seizures; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Parkinson's disease (PD), Alzheimer's disease (AD), dementia, mild cognitive impairment (MCI), Huntington's disease (HD); pharmaceutical preparations for the treatment of loss of memory, cognition, or loss of neuronal functions associated with neurodegenerative diseases or aging; pharmaceutical preparations for the treatment of neurological diseases, namely, ataxia, sporadic or hereditary ataxias, cerebellar ataxia, parkinsonism ataxia, multiple system atrophy (MSA), Friedreich's ataxia, spinocerebellar ataxia, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), muscular dystrophy; pharmaceutical preparations for the treatment of neurodevelopmental disorders, namely, Tourette syndrome (TS), autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), developmental language disorder (DLD), Fragile-X syndrome (FXS), Rett syndrome, cerebral palsy; pharmaceutical preparations for the treatment of pain, namely, neuropathic pain; Pharmaceutical preparations for the treatment of inflammatory disorder or diseases, namely, inflammasome-related diseases, immunological diseases; pharmaceutical preparations for the treatment of auto-inflammatory diseases or auto-immune diseases, namely, multiple sclerosis (MS), systemic sclerosis (SSc), rheumatoid arthritis (RA), lupus, gout, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, chronic inflammation, auto-inflammatory fever syndromes, cryopyrin-associated periodic syndromes (CAPS); pharmaceutical preparations for the treatment of liver-related inflammatory diseases, namely, chronic liver disease, non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis, non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, viral hepatitis; pharmaceutical preparations for the treatment of kidney-related inflammatory diseases, namely, chronic kidney disease (CKD), hypertensive nephropathy, lupus nephritis, Type I diabetes, Type II diabetes, hemodialysis related inflammation; pharmaceutical preparations for the treatment of cardiovascular-related inflammatory diseases, namely, chronic heart disease (CHD), peripheral artery disease (PAD), hypertension, atherosclerosis, acute heart failure, systemic lupus erythematosus (SLE); pharmaceutical preparations for the treatment of neuroinflammation-related diseases, namely, Parkinson's disease (PD), Alzheimer's disease (AD), dementia, mild cognitive impairment (MCI), Huntington's disease (HD), traumatic brain injury (TBI), brain ischemia, ataxia, multiple system atrophy (MSA), Friedreich's ataxia, spinocerebellar ataxia, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), multiple sclerosis (MS), muscular dystrophy, Tourette syndrome (TS), autism spectrum disorder (ASD), Fragile-X syndrome (FXS), Rett syndrome, cerebral palsy; pharmaceutical preparations for the treatment of age-related inflammatory degenerative diseases, namely, Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), parkinsonism-dementia complex of Guam, atherosclerosis, osteoarthritis, neuronal cell death; Pharmaceutical drugs, namely, anti-inflammatory agents, antioxidants, antidepressants, antipsychotics, anti-Parkinson agents, central nervous system agents, stimulants, inhibitors, modulators, benzodiazepines, serotoninergic agents, dopaminergic agents, glutaminergic agents, analgesics, neuromuscular agents, and psychotherapeutic agents

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateMonday, August 23, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameYODA PHARMACEUTICALS INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressGrand Cayman KY1-1002
KY

Party NameYODA PHARMACEUTICALS INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressGrand Cayman KY1-1002
KY

Trademark Events


Event DateEvent Description
Tuesday, August 24, 2021ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Monday, August 23, 2021ABANDONMENT - AFTER PUBLICATION
Monday, August 16, 2021TEAS EXPRESS ABANDONMENT RECEIVED
Tuesday, July 20, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 20, 2021PUBLISHED FOR OPPOSITION
Wednesday, June 30, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, June 14, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, May 29, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, May 28, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, May 28, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, December 7, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, December 7, 2020NON-FINAL ACTION E-MAILED
Monday, December 7, 2020NON-FINAL ACTION WRITTEN
Saturday, December 5, 2020ASSIGNED TO EXAMINER
Saturday, September 12, 2020NOTICE OF DESIGN SEARCH CODE E-MAILED
Friday, September 11, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, August 14, 2020NEW APPLICATION ENTERED IN TRAM